FDA posted the letter on December 17, 2024. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1
What does the letter say, in brief?
| Company | Swisschems |
| Location | New York, NY |
| Website named | swisschems.is, facebook.com, instagram.com |
| Letter dated | December 10, 2024 |
| Posted by FDA | December 17, 2024 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| FDA’s subject line | Unapproved New Drugs/Misbranded |
| Drugs named | semaglutide and retatrutide |
| Kind of letter | Other |
| Reply asked within | fifteen working days |
| Close-out letter | None posted as of November 20, 2026 |
| FDA record | MARCS-CMS 695663 |
What did FDA quote?
The letter quotes 4 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1
Peer-Reviewed Studies . . . Once-weekly semaglutide in adults with overweight or obesity. . .. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
Ready to elevate your research? Semaglutide, a key player in metabolic and weight regulation is now available! Don’t miss this chance to explore its role in glucose regulation, energy balance, and more. . .. Special Offer: Buy 3 or more and get 10% OFF your order! Stock up now for your next breakthrough. #Semaglutide #MetabolicStudies . . . #GlucoseRegulation
Retatrutide (LY-3437943) is a promising anti-obesity agent. It is designed to be a triple hormone receptor agonist, meaning it activates three important receptors in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). These receptors play crucial roles in regulating glucose levels and metabolic functions in the body.
Peer-Reviewed Studies . . . Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial . . . Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Which parts of the law did FDA cite?
The letter cites 2 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.
| Section | What it says | Letters citing it |
|---|---|---|
| 505(a) | A new drug may not be sold across state lines without an approved application | 48 |
| 301(d) | It is prohibited to introduce a drug into interstate commerce in violation of section 505 | 48 |
What did FDA ask the company to do?
In the letter’s own words:
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations.
If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.
FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1
Has FDA warned the seller I use?
Type a seller’s name or website. The search runs over all 164 letters in this database.
How many GLP-1 letters has FDA sent?
16 letters in this database are of the same kind as this one, other matters, such as a clinical investigator or a supplement. 151 of the 164 letters name semaglutide. 21 of the 164 letters name retatrutide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.
Which other sellers got a similar letter?
What does an FDA warning letter mean for someone buying from this seller?
FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.
FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.
A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.
What is the full text of the letter?
This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1
Read the full letter (818 words)
December 10, 2024
Dear Swisschems:
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https://swisschems.is/ in October 2024 and has observed that your website offers “Semaglutide” and “Retatrutide” products for sale in the United States. We have also reviewed your Facebook social media website at https://www.facebook.com/swisschems.is/ and your Instagram social media website at https://www.instagram.com/swisschemsupgraded where you direct consumers to your websites at https://swisschems.is/ to purchase your products. As described below, your “Semaglutide” and “Retatrutide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).
Despite statements on your product labeling marketing your products as “research chemicals only,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and/or affect the structure or function of the body. Examples of claims observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:
Semaglutide
On the product webpage for “Semaglutide,” https://swisschems.is/product/semaglutide-3mg-1-vial/:
- “Peer-Reviewed Studies . . . Once-weekly semaglutide in adults with overweight or obesity. . .. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.”
On a September 18, 2024, post from your Facebook social media website, https://www.facebook.com/swisschems.is/ and your Instagram social media website, https://www.instagram.com/swisschemsupgraded:
- “Ready to elevate your research? Semaglutide, a key player in metabolic and weight regulation is now available! Don’t miss this chance to explore its role in glucose regulation, energy balance, and more. . .. Special Offer: Buy 3 or more and get 10% OFF your order! Stock up now for your next breakthrough. #Semaglutide #MetabolicStudies . . . #GlucoseRegulation”
Retatrutide
On the product webpage “Retatrutide,” https://swisschems.is/product/retatrutide-5mg/:
- “Retatrutide (LY-3437943) is a promising anti-obesity agent. It is designed to be a triple hormone receptor agonist, meaning it activates three important receptors in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). These receptors play crucial roles in regulating glucose levels and metabolic functions in the body.”
- “Peer-Reviewed Studies . . . Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial . . . Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA”
Your “Semaglutide” and “Retatrutide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
Conclusion
This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.
Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.
Sincerely,
/s/
Tina Smith, M.S
Captain, U.S Public Health Service
Director
Office of Unapproved Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration
Content current as of:
12/17/2024
Regulated Product(s)
Drugs
Sources
- FDA. Warning letter to Swisschems, December 10, 2024 (MARCS-CMS 695663). fda.gov
- FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
- FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider